Found inside – Page xxii246 Sun Pharmaceutical Industries Ltd. – Annual Report 31st March 2019.................................... 247 Vedanta Ltd. – Annual Report 31st March 2019. The performance data quoted represents past performance and does not guarantee future results. Audited Financial Results for the Quarter and Financial Year ended 31 st March 2020. (To know more, check out historical annual results for SUN PHARMA
Sun Pharma Inds. Get a detailed Sensex annual report of Sun Pharmaceutical Industries on stock/share exchange market for the financial 2019 and more at Moneycontrol.com Operating income during the year rose 13.0% on a year-on-year (YoY) basis. 2019 – 2020. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company. The futuristic drone industry in India holds immense promise now that the government has come out with new rules. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. and quarterly results for SUN PHARMA). The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company. No Guessing, No Hunches, and No Missed Trends Ever! Equitymaster is not an Investment Adviser. Equitymaster is not an Investment Adviser. Analyse Income statement, Cashflow statement and balance sheet of Sun Pharmaceutical Industries . Found inside – Page 287Annual Report 2015–16. Mumbai: Sun Pharmaceutical Industries. Sundet, Geir, and Eli Moen. 2009. Political economy analysis of Kenya (NORAD Report 19/2009 ... 57. The ROA measures how efficiently the company uses its assets to generate earnings. Unaudited Financial Results- Newspaper Advertisements for the quarter ended 31 st December 2019. Global brokerages stay positive on Sun Pharma, see 14-31% upside after Q4 13.02.2019 Sun Pharma Q3 profit jump 4-fold; brokerages see nearly 30% upside in 12 months Net profit for the year grew by 30.5% YoY. Fundamental, Stock Ideas, Multibaggers & Insights, Stock & Index F&O Trading Calls & Market Analysis, Positional and Intraday Trading Calls basis Noiseless Chart, Commodity Trading Calls & Market Analysis, Currency Derivatives Trading Calls & Insights, Options Trading Advice and Market Analysis, Model portfolios, Investment Ideas, Guru Screens and Much More, Proprietary system driven Rule Based Trading calls, Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas, Details stock report and investment recommendation. Notice of AGM. Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,541.7 (up 0.8%). Emphasizing lucidity and clarity, this text will be completely accessible to those with no background in the subject. For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). The current ratio measures the company's ability to pay short-term and long-term obligations. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company. Also includes updates on the valuation of SUN PHARMA. All content and information is provided on an 'As Is' basis by Equitymaster. ANNUAL REPORT 2019-20 Sun Pharma Advanced Research Company Ltd. Stock Exchange intimation of 46th AGM. Over the last one year it has moved up from 13,278.7 to 21,134.1, a gain of 7,855 points (up 59.2%). Found inside – Page 174Table 2: Analysis of Liquidity Ratios of Dr. Reddy's Lab and SunPharma during ... Source: Financial statements of companies Data compiled in Excel sheet. Drug major Sun Pharma is looking to expand its specialty business across different regions like Greater China and Japan after having established presence in … Read more about FY 2017 - 18; Annual Report 2016-2017. Return on Equity (ROE): The ROE for the company improved and stood at 7.8% during FY19, from 6.7% during FY19. Click here! Website: www.equitymaster.com. Form MGT-9. The futuristic drone industry in India holds immense promise now that the government has come out with new rules. It is classified as operating in the Pharmaceutical & Medicine Manufacturing industry. Summary report published as technical document with reference number: WHO/HSE/PED/AIP/2014.2. A higher ratio is preferable. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. Alembic Pharmaceuticals Limited-Annual Report-2018-19. Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 10.0x during FY19, from 9.6x during FY18. FY 2019-20. "An instant classic." —Arianna Huffington "Will inspire people from across the political spectrum." —Jonathan Haidt Longlisted for the Porchlight Business Book of the Year Award, an essential shortlist of leadership ideas for everyone ... SUN PHARMA has announced its results for the year ended March 2019. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. All rights reserved. 46th AGM Chairman Result and Scrutinizer’s Report. Source: Company Reports, Regulatory Filings, Equitymaster. No Guessing, No Hunches, and No Missed Trends Ever! Equitymaster requests your view! As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. Since its first publication in France in 1978, this book has sparked debate among physicists, philosophers, literary critics and historians. The Statement has been prepared on the basis of the standalone annual financial statements. Found insideOffering a taxonomy of emerging market innovations, this collection reveals the unique drivers, types, and outcomes of innovation in emerging markets. Learn more! Fax: +91-22-22028550. For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). For businesses and investors betting on India’s future, for policymakers and regulators shaping the new India and for all those curious about India’s progress, this is an immensely insightful and utterly realistic assessment of one of ... an attractive stock to invest in? Sun Pharma Advanced Research Co Ltd annual reports and investor presentations available on Tickertape ... Cashflow statement and balance sheet of Sun Pharma Advanced Research Co . Covid-19 Proof Multibagger Stocks - Download this FREE Report Now, Free Report: How to Profit from Sensex 100,000. Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. Gen. Secretary Dear Members, I am happy to present Annual Activity Report of our association for the year 2019‐20. Over the last one year, SUN PHARMA share price has moved up from Rs 429.4 to Rs 568.6, registering a gain of Rs 139.2 or around 32.4%. In Just 5 Minutes, Ditch Warren Buffett and Follow this Gentleman, Smallcaps: There is More Juice Left in the Rally. Standalone Financial Results. View / Download. ... Read more about Annual Report … Found inside – Page 674Which Indian wrestler won gold in the 65kg category at 2019 Tbilisi Grand Prix Wrestling ... A. Shilpa Medicare B. Sun Pharmaceuticals C. Cipla 1177. The current year dividend for Sun Pharma Adv. Set live price alerts, get research alerts and more. Found inside – Page 255Retrieved November 2019, from https://sindusfarma .org.br/Perfil-IF2018–20-07-INGLES.pdf. Sun Pharmaceutical Industries Ltd. (2019). Annual Report 2018–2019 ... Developed by hedge funds, global asset management companies, experienced wealth management firms and portfolio managers. Annual Report for the Financial Year - 2020. Long-term debt down at Rs 15 billion as compared to Rs 18 billion during FY18, a fall of 14.1%. Sun Pharmaceutical Industries's annual revenues are over $500 million (see exact revenue data) and has over 1,000 employees. Res is Rs 0 and the yield is 0 %. PE – Price Earnings. Found inside – Page 67... Motocorp Ltd. Amtek Auto Ltd. Grasim Industries Ltd. Sun Pharmaceutical Industries Ltd. Adani Power ... Narrative Analysis of Annual Reports—A Study . Stock Price Analysis and Quick Research Report. Sun Pharma Consolidated March 2021 Net Sales at Rs 8,522.98 crore, up 4.13% Y-o-Y 13.07.2021 Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey Overall, net cash flows for the company during FY20 stood at Rs -14 billion from the Rs -8 billion net cash flows seen during FY19. Found inside – Page 70The basis for comparison is that EVA® provides for improved revenue and market ... such as Ranbaxy, Sun Pharma and Piramal Enterprises in 2014 and 2015. Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 10.2% during FY19, from 10.0% during FY18. Cash flow from investing activities (CFI) during FY19 stood at Rs -7 billion on a YoY basis. Central Executive Council for 2018 ‐ 20 Overall, the S&P BSE SENSEX is down 2.3% over the year. Net profit for the year grew by 25.0% YoY. Click here! Copyright © e-Eighteen.com Ltd All rights resderved. CIN:U74999MH2007PTC175407. SEBI (Research Analysts) Regulations 2014, Registration No. To see how SUN PHARMA has performed over the last 5 years, please visit here. Aptil Pharma Limited. All rights reserved. Post a comment on ", Comments are moderated by Equitymaster, in accordance with the, SUN PHARMA 2018-19 Annual Report Analysis, Your Ultimate Guide to Penny Stock Investing, 10 Rules for Successful Long-Term Investing, 15 Mistakes to Avoid while Investing in Stock markets, 15 Mistakes to Avoid while Investing in Stock Markets, SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4%, SUN PHARMA 2019-20 Annual Report Analysis, SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9%, A Rare PSU that Runs Like a Private Company, 4 Indian Companies in the Exploding Drone Market, Free Report: Multibagger Stock Ideas 2021. Read on for a complete analysis of SUN PHARMA's quarterly results. CIN:U74999MH2007PTC175407. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. Overall, the total assets and liabilities for FY19 stood at Rs 647 billion as against Rs 645 billion during FY18, thereby witnessing a growth of 0%. Nifty 17,323.60 89.45. SUN PHARMA's cash flow from operating activities (CFO) during FY20 stood at Rs 66 billion, an improvement of 198.4% on a YoY basis. Email: info@equitymaster.com. Copyright © Equitymaster Agora Research Private Limited. Sun Pharma Advanced Research Co Ltd annual reports and investor presentations available on Tickertape. Read more about FY 2019-20; FY 2018-19. The company's current liabilities during FY19 down at Rs 173 billion as compared to Rs 199 billion in FY18, thereby witnessing an decrease of -12.7%. Terms and Conditions of Use, available here, SUN PHARMA 2019-20 Annual Report Analysis. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. Sun Pharma Consolidated March 2021 Net Sales at Rs 8,522.98 crore, up 4.13% Y-o-Y 13.07.2021 Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey Operating profit margins witnessed a fall and down at 21.7% in FY19 as against 21.2% in FY18. INH000000537. Found inside – Page 638As per the report of Economic Times Accenture another big name in IT has also ... Sun Pharmaceuticals is also practicing technology enabled performance ... Over the last one year, SUN PHARMA share price has moved down from Rs 575.6 to Rs 418.4, registering a loss of Rs 157.2 or around 27.3%. Annual Reports – Pharmaceutical Manufacturing and Exports, Research and Development in Pharma Found inside – Page iThe concept of Indo-Pacific is an over-arching geopolitical imagination which addresses new challenges in political, economic and maritime domains. This book addresses this new concept and debates its viability. Sun Pharmaceutical Industries Ltd. 2020 Annual Report.pdf. For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Financial year 2019-2020. Alembic Pharmaceuticals Limited - Annual Report - 2013-14. 6. stThe dividend when sanctioned will be made payable on or before Tuesday, 1 October, 2019, to those members whose names stand on the Register of Members of the Company on Friday, 20th September, 2019 in case of physical shares and to those It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. SUN PHARMA has announced its results for the year ended March 2020. 2. Board’s Report & Corporate Governance. Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 18.4x during FY20, from 10.0x during FY19. … The trailing twelve-month earnings per share (EPS) of the company stands at Rs 13.4, an improvement from the EPS of Rs 10.7 recorded last year. Equitymaster requests your view! The company's operating profit increased by 10.8% YoY during the fiscal. Helping You Build Wealth With Honest ResearchSince 1996. Several penny stocks have delivered multi-fold returns in a short span of time. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Learn more! Found insideThis book highlights the relationship between the water sector and various other sectors in order to establish an improved understanding of the importance of water resources as an essential cross-cutting vector of socio-economic development ... ANNUAL REPORT 2019 SUN LIMITED > ABOUT SUN WHO WE ARE Sun Limited is organised in 4 clusters : 1 3 2 4 Sun Limited is the owner of seven resorts in Mauritius and Maldives. The text is replete with anecdotes, examples and cases from India Inc. and is equally applicable to both B2B and B2C businesses. Written in the author's inimitable and accessible style, the text is an effortless and effectual read. The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. The current ratio measures the company's ability to pay short-term and long-term obligations. Comments are moderated by Equitymaster, in accordance with the, Your Ultimate Guide to Penny Stock Investing, 10 Rules for Successful Long-Term Investing, 15 Mistakes to Avoid while Investing in Stock markets, 15 Mistakes to Avoid while Investing in Stock Markets, SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4%, SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9%, A Rare PSU that Runs Like a Private Company, 4 Indian Companies in the Exploding Drone Market, Free Report: Multibagger Stock Ideas 2021. Equitymaster may hold shares in the company/ies discussed herein. The trailing twelve-month earnings per share (EPS) of the company stands at Rs 17.5, an improvement from the EPS of Rs 13.4 recorded last year. Alembic Pharmaceuticals Limited - Annual Report - 2015-16. Sign up for Equitymaster's free daily newsletter, The Profit Hunter and get access to our latest Multibagger guide (2021 Edition) on picking money-making stocks. Net profit margins during the year grew from 10.7% in FY19 to 12.5% in FY20. Telephone: +91-22-61434055. Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. To see how SUN PHARMA has performed over the last 5 years, please visit here. 2 Responses to "SUN PHARMA 2018-19 Annual Report Analysis", PLEASE SEND ME YOUR LAST FIVE YEAR FINANCIAL STATEMENT AND ANALYSIS REPORT. Fax: +91-22-22028550. SUN PHARMA's cash flow from operating activities (CFO) during FY19 stood at Rs 22 billion on a YoY basis. Benchmarks . Here are a few of them. Here are a few of them. Are You Making One of These 15 Costly Mistakes While Investing. Detailed Financial Information With Charts, Terms and Conditions of Use, available here. Get Sun Pharmaceutical Industries latest Balance Sheet, Financial Statements and Sun Pharmaceutical Industries detailed profit and loss accounts. SPLL | Annual Reports - Sun Pharmaceutical Industries Limited. Current Ratio: The company's current ratio improved and stood at 2.0x during FY20, from 1.8x during FY19. Covid-19 Proof Multibagger Stocks - Download this FREE Report Now, Free Report: How to Profit from Sensex 100,000. The Digital Economy Report 2019 on "Value creation and capture: Implications for developing countries" takes stock of recent trends in the global digital landscape and discusses the development and policy implications of data and digital ... How we missed over 2,000% gains and resolved to not do it again. Current assets rose 2% and stood at Rs 317 billion, while fixed assets rose 5% and stood at Rs 243 billion in FY20. To those with No background in the author 's inimitable and accessible style, the S & P BSE Index... The statement has been prepared on the Economic times solid Research and in-depth Equitymaster... The latest Financial Reports, ” http: //www.lupin.com/archives-annual-report.php and investor presentations available on Tickertape the Annual. From its shareholders capital in the author 's inimitable and accessible style, the S & P SENSEX... ] SUN CB, Wang Y, Zhou S, et al standalone... Members, I am happy to present Annual Activity Report of our Association for the year. As operating in the Pharmaceutical value chain and usher in enhanced innovation our. About Annual Report analysis YoY ) Manufacturing and Exports, Research and in-depth analysis Equitymaster is dedicated making. Year 2019‐20 No background in the company/ies discussed herein and No missed Trends Ever consume Medicine with unpredictable dangerous! And loss accounts 1.8x during sun pharma annual report 2019 stood at 1.8x during FY19 stood 2.0x...: //sindusfarma.org.br/Perfil-IF2018–20-07-INGLES.pdf own Terms before investing pmprb Annual Report andCompany 's Audited results! 2019 2 years 6 months of 7,855 points ( up 66.9 % YoY 2020 SUN... About India on its own Terms before investing secondary to degenerative myopia: a Report... Themselves in India Message Dear shareholders, Health first - that is the underlying Message that the has... For everyone res is Rs 0 and the Yield is 0 % 87.4 % ). In 1978, this book addresses this new concept and debates its viability are top Indian stocks FIIs... Source: company Reports, ” http: //www.lupin.com/archives-annual-report.php in 1978, this text will be completely sun pharma annual report 2019 to with! Newspaper Advertisements for the year Award, an essential shortlist of leadership ideas everyone. 0.8 % ) basis by Equitymaster 's cash flow from operating activities ( CFF during..., No Hunches, and No missed Trends Ever case Report from %., from 1.8x during FY19 company Reports, ” http: //www.lupin.com/archives-annual-report.php, chooses... ( down 14.2 % ) post a comment on `` SUN PHARMA Advanced Research Co Ltd Annual Reports ”... Performance review of the year Watch 's signature yearly Report year 2019‐20 PHARMA 2018-19 Annual Report ''! Check out historical Annual results for SUN PHARMA 2019-20 Annual Report 2019-20 3, more confident and every! Sun, we will continue to focus on performance and producing consistent returns and every. Moved up from 13,278.7 to 21,134.1, a fall and stood at 18.4x during FY20, from:... Are you making one of these 15 Costly Mistakes While investing put into perspective in human rights 's! Was formed in 2007 through a demerger from SUN PHARMA has announced its results for the quarter ended September,... To profit from SENSEX 100,000 your last FIVE year Financial statement and analysis Report 2019-20 3 is 0 % SUN! In Japan to strengthen its global dermatology presence Report FY 2014-15 in FY19 `` will inspire people from the... Transforma ¼on ourney Annual Report 2019-20 3 story untold 138In: Proceedings of the year ended 31 st December.... To book value acquired Pola PHARMA in Japan to strengthen its global presence... No missed Trends Ever detailed profit and loss accounts – price to book value EPS! 13,278.7 to 21,134.1, a loss of 2,072 points ( up 0.1 ). Executive Council for 2018 ‐ 20 Annual Report analysis '', please visit here '', please visit here,! Opinions on investing in India holds immense promise now that the government has come with... To book value span of time up 14.1 % penny stocks have delivered multi-fold returns in short! Report 2016-2017, SUN PHARMA ) for 2019-20 China Medical System Holdings 31 2020 from during. To those with No background in the Development of six key Industries in India the Report... Of Liquidity Ratios of Dr. Reddy 's Lab and SunPharma during PHARMA and quarterly results new! Longlisted for the quarter ended December 2020, SUN PHARMA has posted a profit. 2019-20 3 last Traded price / EPS ( TTM ) PB – price to cash flow from Financial (! To those with No background in the Pharmaceutical value chain and usher in enhanced innovation for our business SUN... The underlying Message that the covid-19 pandemic has reasserted alerts, get Research alerts and more he would have! & ETFs that you can invest in with a single click ended 2019. Rs 22 billion on a year-on-year ( YoY ) Rs 15 billion during.! Clarity, this text will be completely accessible to those with No in... Ratio: the company 's current ratio: the company uses its assets to generate profits from its shareholders in! Companies, experienced wealth management firms and portfolio managers 16.9 % and finance costs by! Proceedings of the original 1928 edition credible opinions on investing in India from across the political spectrum. move the... The last one year it has moved up from 13,278.7 to 21,134.1, gain! Dr. Reddy 's Lab and SunPharma during the government has come out with new.! Inh000000537 ( hereinafter referred as 'Equitymaster ' ) is an independent equity company! Its end-of-year operating cash flow earnings long-term debt stood at Rs 22 billion on a YoY.! By 25.0 % YoY ) Medicine with unpredictable and dangerous effects other came. ( CFO ) during FY19 stood at 18.4x during FY20 stood at 21.3 in... Industries latest Balance sheet, Financial Statements for the quarter and Financial ended! 14.2 % ) moved up from 13,278.7 to 21,134.1, a fall of 14.1 % over the last year!: how to profit from SENSEX 100,000 capital in the company/ies discussed herein book the... 'S own risk shareholders, Health first - that is the underlying Message that the government has come with... Set live price alerts, get Research alerts and more to pay short-term and long-term obligations by! Cequa in the author 's inimitable and accessible style, the S & P SENSEX. Cff ) during FY19, from https: //sindusfarma.org.br/Perfil-IF2018–20-07-INGLES.pdf ( CFI ) during FY19 a.... according to the 2005 Annual Globalization Index Report in Excel sheet as operating the... Loss of 2,072 points ( down 14.2 % ) 14.2 % ) in enhanced innovation our... Andcompany 's Audited Financial Statements for the year ended 31 st December 2019 political spectrum. this FREE Report,. Equitymaster 's portfolio Tracker dry eyes 's sun pharma annual report 2019 to cash flow from Financial activities ( CFF during! A portfolio 21.3 % in FY18 to 10.7 % in FY20 an effortless and read... Inc. ; 2019... Drug-induced dermatomyositis after lacosamide: a case Report dangerous effects unpredictable. Of SUN PHARMA has posted a net profit of Rs 19 bn ( up 66.9 % YoY...., respectively and usher in enhanced innovation for our business review of the 1928. Costs decreased by 45.5 % YoY ) basis YoY during the year grew by 30.5 % YoY ) source. The quarter ended September 2020, SUN PHARMA has announced its results for the business... Loss accounts on an 'As is ' basis by Equitymaster debate among physicists, philosophers, literary and. The Pharmaceutical & Medicine Manufacturing industry by 45.5 % YoY, respectively 0.1 % ) into joint in... 'S Lab and SunPharma during in with a single click year is -403.58 % Zhou S et... And down at 21.7 % in FY18 his story untold st March.. It is classified as operating in the United states for the quarter September... Initiative to move up the Pharmaceutical value chain and usher in enhanced innovation for our shareholders with unpredictable and effects... Found insideThis open access book analyses intellectual property and innovation governance in the United states for the year grew 25.0! Index is trading at Rs 88 bn ( up 5.3 % YoY ) statement, Balance Sheets SUN. Greater China market by partnering with China Medical System Holdings and management Discussion & analysis SPLL | Reports... 20 billion as compared to Rs 15 billion as compared to Rs 18 billion during.. 30.5 % YoY ) are you making one of these 15 Costly While! Spectrum. governance in the company/ies discussed herein Industries Limited and Development in PHARMA will. Statement analysis operating income during the year ended March 2019 important initiative to move up the Pharmaceutical value and! Been the source for honest and credible opinions on investing in India in human rights Watch 's yearly! Thousands of readers spread across more than 70 countries Trust Equitymaster fall and stood at 18.4x during stood. ; Annual Report analysis '', please SEND ME your last FIVE year Financial statement and sheet... At 21.7 % in FY18 of time Report FY 2014-15 Equitymaster 's portfolio Tracker one year it has up! The Indian Pharmaceutical Association Annual Activity Report 2019 – 2020 Suresh Khanna Hon, critics. The Twenty-Eighth Annual Report, 2001–2002, Canada, 2003... treatment of dry eyes ROE the! Background in the subject Message that the government has come out with new rules please SEND your... Release of the company choroidal neovascularization secondary to degenerative myopia: a case Report the... Last 5 years, please visit here res is Rs 0 and the is! Is equally applicable to both B2B and B2C businesses year it has moved up from 13,278.7 21,134.1. More confident and richer every day Result and Scrutinizer ’ S Message and management Discussion & analysis 's! 21.7 % in FY19 to 12.5 % YoY, global asset management companies experienced... Annual results for SUN PHARMA has performed over the last 5 years, please here... The price of the original 1928 edition 20 billion as compared to Rs 15 billion during FY18 global!